Next Article in Journal
Use of Generalized Weighted Quantile Sum Regressions of Tumor Necrosis Factor Alpha and Kidney Function to Explore Joint Effects of Multiple Metals in Blood
Next Article in Special Issue
Patient Experiences after Physical Trauma: The Negative Effect of the COVID-19 Pandemic on Recovery
Previous Article in Journal
An Exploration of Dance Learning Stress Sources of Elementary School Dance Class Students with Artistic Abilities: The Influences of Psychological Capital and Self-Concept
Previous Article in Special Issue
A COVID-19 Survey among People Who Use Drugs in Norway
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJERPH
Volume 19
Issue 12
10.3390/ijerph19127397
ijerph-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Trazodone Prolonged-Release Monotherapy in Cannabis Dependent Patients during Lockdown Due to COVID-19 Pandemic: A Case Series

by
Marianna Mazza
1,2,*,†,
Emanuele Caroppo
3,†,
Giuseppe Marano
1,2,
Georgios D. Kotzalidis
1,2,4,
Carla Avallone
1,2,
Giovanni Camardese
1,2,
Delfina Janiri
1,2,
Lorenzo Moccia
1,2,
Alessio Simonetti
1,2,
Luigi Janiri
1,2 and
Gabriele Sani
1,2
1
Institute of Psychiatry and Psychology, Department of Geriatrics, Neuroscience and Orthopedics, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy
2
Department of Psychiatry, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
3
Department of Mental Health, Local Health Authority Roma 2, 00159 Rome, Italy
4
Department of Neurosciences, Mental Health, and Sensory Organs (NESMOS), Sapienza University of Rome, 00189 Rome, Italy
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Int. J. Environ. Res. Public Health 2022, 19(12), 7397; https://doi.org/10.3390/ijerph19127397
Submission received: 1 May 2022 / Revised: 15 June 2022 / Accepted: 15 June 2022 / Published: 16 June 2022
(This article belongs to the Special Issue Mental Health and Substance Use Disorders during the COVID-19 Pandemic)
Browse Figures
Review Reports Versions Notes

Abstract

(1) Background: During the SARS-CoV-2 (COVID-19) pandemic, cannabis use increased relative to pre-pandemic levels, while forced home confinement frequently caused sleep/wake cycle disruptions, psychological distress, and maladaptive coping strategies with the consequent appearance of anxiety symptoms and their potential impact on substance use problems. (2) Aim: Long-acting trazodone (150 mg or 300 mg daily) has a potential benefit as monotherapy in patients with cannabis use disorder. The present work aims to investigate the effectiveness of trazodone in optimizing the condition of people with cannabis dependence under pandemic conditions. (3) Methods: All cases with cannabis use disorder were uniformly treated with long-acting trazodone 150 mg or 300 mg/day; their craving and clinical status were monitored through appropriate psychometric scales. Side effects were recorded as they were reported by patients. We described the cases of three young patients—one man and two women—who were affected by chronic cannabis use disorder and who experienced lockdown-related psychological distress and sought psychiatric help. (4) Results: The described cases highlight that the once-a-day formulation of trazodone seems to have a therapeutic role in patients with cannabis use disorder and to guarantee tolerability and efficacy over time. No significant side effects emerged. (5) Conclusions: The use of long-acting trazodone (150 mg or 300 mg daily) has a potential benefit as monotherapy in patients with cannabis use disorder. Trazodone deserves to be studied in terms of its efficacy for cannabis use disorder.
Keywords: trazodone; COVID-19; cannabis use disorder; sleep disorders; anxiety trazodone; COVID-19; cannabis use disorder; sleep disorders; anxiety
Graphical Abstract

Share and Cite

MDPI and ACS Style

Mazza, M.; Caroppo, E.; Marano, G.; Kotzalidis, G.D.; Avallone, C.; Camardese, G.; Janiri, D.; Moccia, L.; Simonetti, A.; Janiri, L.; et al. Trazodone Prolonged-Release Monotherapy in Cannabis Dependent Patients during Lockdown Due to COVID-19 Pandemic: A Case Series. Int. J. Environ. Res. Public Health 2022, 19, 7397. https://doi.org/10.3390/ijerph19127397

AMA Style

Mazza M, Caroppo E, Marano G, Kotzalidis GD, Avallone C, Camardese G, Janiri D, Moccia L, Simonetti A, Janiri L, et al. Trazodone Prolonged-Release Monotherapy in Cannabis Dependent Patients during Lockdown Due to COVID-19 Pandemic: A Case Series. International Journal of Environmental Research and Public Health. 2022; 19(12):7397. https://doi.org/10.3390/ijerph19127397

Chicago/Turabian Style

Mazza, Marianna, Emanuele Caroppo, Giuseppe Marano, Georgios D. Kotzalidis, Carla Avallone, Giovanni Camardese, Delfina Janiri, Lorenzo Moccia, Alessio Simonetti, Luigi Janiri, and et al. 2022. "Trazodone Prolonged-Release Monotherapy in Cannabis Dependent Patients during Lockdown Due to COVID-19 Pandemic: A Case Series" International Journal of Environmental Research and Public Health 19, no. 12: 7397. https://doi.org/10.3390/ijerph19127397

APA Style

Mazza, M., Caroppo, E., Marano, G., Kotzalidis, G. D., Avallone, C., Camardese, G., Janiri, D., Moccia, L., Simonetti, A., Janiri, L., & Sani, G. (2022). Trazodone Prolonged-Release Monotherapy in Cannabis Dependent Patients during Lockdown Due to COVID-19 Pandemic: A Case Series. International Journal of Environmental Research and Public Health, 19(12), 7397. https://doi.org/10.3390/ijerph19127397

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop